Exploration of potential EGFR inhibitors: a combination of pharmacophore-based virtual screening, atom-based 3D-QSAR and molecular docking analysis

References

• Seymore L. Novel anti-cancer agents in development: exciting prospects and new challenges. Cancer Treat Rev 1999;25:301–12
   PubMed Web of Science ®Google Scholar
• Buolamwini JK. Novel molecular targets for cancer drug discovery. In: Coleman WB, Tsongalis GJ, eds. The molecular basis of human cancer. Totowa, NJ: Humana Press; 2002:521–40
   Google Scholar
• Paul MK, Mukhopadhyay AK. Tyrosine kinase – role and significance in cancer. Int J Med Sci 2004;1:101–15
   PubMed Web of Science ®Google Scholar
• Hong WK, Ullrich A. The role of EGFR in solid tumors and implications for therapy. Oncol Biother 2000;1:1–29
   Google Scholar
• Kolibaba KS, Druker BJ. Protein tyrosine kinases and cancer. Biochim Biophys Acta 1997;1333:217–48
   PubMed Web of Science ®Google Scholar
• Assefa H, Kamath S, Buolamwini JK. 3D-QSAR and docking studies on 4-anilinoquinazoline and 4-anilinoquinoline epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors. J Comput Aid Mol Des 2003;17:475–93
   PubMed Web of Science ®Google Scholar
• Woodburn JR. The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Therapeut 1999;82:241–50
   PubMed Web of Science ®Google Scholar
• Ma XH, Wang R, Tan CY, et al. Virtual screening of selective multitarget kinase inhibitors by combinatorial support vector machines. Mol Pharm 2010;7:1545–60
   PubMed Web of Science ®Google Scholar
• Abouzid K, Shouman S. Design, synthesis and in vitro antitumor activity of 4-aminoquinoline and 4-aminoquinazoline derivatives targeting EGFR tyrosine kinase. Bioorg Med Chem 2008;16:7543–51
   PubMed Web of Science ®Google Scholar
• Pawar VG, Sos ML, Rode HB, et al. Synthesis and biological evaluation of 4-anilinoquinolines as potent inhibitors of epidermal growth factor receptor. J Med Chem 2010;53:2892–901
   PubMed Web of Science ®Google Scholar
• Klutchko SR, Hamby JM, Boschelli DH, et al. 2- substituted aminopyrido [2, 3-d] pyrimidin-7(8H)-ones. Structure-activity relationships against selected tyrosine kinases and in vitro and in vivo anticancer activity. J Med Chem 1998;41:3276–92
   PubMed Web of Science ®Google Scholar
• Solca FF, Baum A, Langkopf E, et al. Inhibition of epidermal growth factor receptor activity by two pyrimidopyrimidine derivatives. J Pharmacol Exp Ther 2004;311:502–9
   PubMed Web of Science ®Google Scholar
• Ding G, Lu Y, Nikolovska-Coleska Z, et al. Structure based design of spiro-oxindoles as potent, specific small-molecule inhibitors of the MDM2-p53 interaction. J Med Chem 2006;49:3432–5
   PubMed Web of Science ®Google Scholar
• Li N, Thompson S, Schultz DC, et al. Discovery of selective inhibitors against EBNA1 via high throughput in silico virtual screening. PLoS One 2010;5:e10126–9
   PubMed Web of Science ®Google Scholar
• Shi WM, Shen Q, Kong W, Ye BX. QSAR analysis of tyrosine kinase inhibitor using modified ant colony optimization and multiple linear regression. Eur J Med Chem 2007;42:81–6
   Google Scholar
• Yang SC, Chang SS, Chen HY, Chen CYC. Identification of potent EGFR inhibitors from TCM Database@Taiwan. PLoS Comput Biol 2011;7:1–10
   Google Scholar
• Sun MF, Yang SC, Chang KW, et al. Screening from TCM Database@Taiwan and QSAR model for identifying HER2 inhibitors. Mol Simulat 2011;37:884–92
   Web of Science ®Google Scholar
• Talele TT, Kulkarni SS, Kulkarni VM. Development of pharmacophore alignment models as input for comparative molecular field analysis of a diverse set of azole antifungal agents. J Chem Inf Comp Sci 1999;39:958–66
   Google Scholar
• Karki RG, Kulkarni VM. A feature based pharmacophore for Candida albicans MyristoylCoA: protein N-myristoyltransferase inhibitors. Eur J Med Chem 2001;36:147–63
   PubMed Web of Science ®Google Scholar
• Burnett JC, Wang C, Nuss JE, et al. Pharmacophore guided lead optimization: the rational design of a non-zinc coordinating, sub-micromolar inhibitor of the botulinum neurotoxin serotype a metalloprotease. Bioorg Med Chem Lett 2009;19:5811–13
   Web of Science ®Google Scholar
• Dayam R, Sanchez T, Clement O, et al. The beta-diketoacid pharmacophore hypothesis 1. The discovery of a novel class of HIV-1 integrase inhibitors. J Med Chem 2005;48:111–20
   PubMed Web of Science ®Google Scholar
• Ishikawa T, Seto M, Banno H, et al. Design and synthesis of novel human epidermal growth factor receptor 2 (HER2) /epidermal growth factor receptor (EGFR) dual inhibitors bearing a pyrrolo [3,2-d] pyrimidine scaffold. J Med Chem 2011;54:8030–50
   PubMed Web of Science ®Google Scholar
• Krovat EM, Langer T. Non-peptide angiotensin II receptor antagonists: chemical feature based pharmacophore identification. J Med Chem 2003;46:716–26
   Google Scholar
• Phase, version 3.4, Schrödinger, LLC, New York, NY, 2012
   Google Scholar
• LigPrep, version 2.5, Schrodinger, LLC, New York, NY, 2012
   Google Scholar
• Evans DA, Doman TN, Thorner DA, Bodkin MJ. 3D QSAR methods: phase and catalyst compared. J Chem Inf Model 2007;47:1248–57
   PubMed Web of Science ®Google Scholar
• Suryanarayanan V, Sudha A, Rajamanikandan S, et al. Atom-based 3D QSAR studies on novel N-β-D-Xylosylindole derivatives as SGLT2 inhibitors. Med Chem Res 2013;22:615–24
   Web of Science ®Google Scholar
• Thangapandian S, John S, Sakkiah S, Lee KW. Potential virtual lead identification in the discovery of renin inhibitors: application of ligand and structure-based pharmacophore modeling approaches. Eur J Med Chem 2011;46:2469–76
   PubMed Web of Science ®Google Scholar
• Aertgeerts K, Skene R, Yano J, et al. Structural analysis of the mechanism of inhibition and allosteric activation of the kinase domain of HER2 protein. J Biol Chem 2011;286:18756–65
   PubMed Web of Science ®Google Scholar
• Schrodinger Suite 2012 Protein Preparation Wizard; Epik, version 2.3, Schrodinger, LLC, New York, NY, 2012; Impact, version 5.8, Schrodinger, LLC, New York, NY, 2012; Prime, version 3.1, Schrodinger, LLC, New York, NY, 2012
   Google Scholar
• Halgren TA, Murphy RB, Friesner RA, et al. Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. J Med Chem 2004;47:1750–9
   PubMed Web of Science ®Google Scholar
• Friesner RA, Murphy RB, Repasky MP, et al. Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. J Med Chem 2006;49:6177–96
   PubMed Web of Science ®Google Scholar
• QikProp, version 3.5, Schrodinger, LLC, New York, NY, 2012
   Google Scholar
• Afroz Alam M, Naik PK. Molecular modelling evaluation of the cytotoxic activity of podophyllotoxin analogues. J Comput Aid Mol Des 2011;23:209–25
   Web of Science ®Google Scholar
• Tropsha A. Best practices for QSAR model development, validation, and exploitation. Mol Inform 2010;29:476–88
   PubMed Web of Science ®Google Scholar
• Dixon SL, Smondyrev AM, Knoll EH, et al. PHASE: a new engine for pharmacophore perception, 3D QSAR model development, and 3D database screening: 1. Methodology and preliminary results. J Comput Aid Mol Des 2006;20:647–71
   PubMed Web of Science ®Google Scholar
• Tawari NR, Degani MS. Predictive models for nucleoside bisubstrate analogs as inhibitors of siderophore biosynthesis in Mycobacterium tuberculosis: pharmacophore mapping and chemometric QSAR study. Mol Divers 2011;15:435–44
   PubMed Web of Science ®Google Scholar
• Sakkiah S, Thangapandian S, John S, et al. 3D QSAR pharmacophore based virtual screening and molecular docking for identification of potential HSP90 inhibitors. Eur J Med Chem 2010;45:2132–40
   PubMed Web of Science ®Google Scholar